tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

CYTK Stock Latest News

Promising Phase 3 Results for Aficamten Boost Cytokinetics’ Market Position in Hypertrophic Cardiomyopathy Treatment
RatingsPromising Phase 3 Results for Aficamten Boost Cytokinetics’ Market Position in Hypertrophic Cardiomyopathy Treatment
23h ago
CYTK
Cytokinetics’ MAPLE Trial Results: Hold Rating Amid Uncertainties in Secondary Outcomes and Market Adoption
PremiumRatings
Cytokinetics’ MAPLE Trial Results: Hold Rating Amid Uncertainties in Secondary Outcomes and Market Adoption
23h ago
CYTK
Cytokinetics’ Promising Phase 3 Trial Results and Market Potential Justify Buy Rating
PremiumRatings
Cytokinetics’ Promising Phase 3 Trial Results and Market Potential Justify Buy Rating
23h ago
CYTK
Cytokinetics’ Aficamten Gains Competitive Edge with Successful Phase 3 Study, Strengthening Market Position
PremiumRatings
Cytokinetics’ Aficamten Gains Competitive Edge with Successful Phase 3 Study, Strengthening Market Position
1d ago
CYTK
Cytokinetics’ Aficamten Shows Promise as First-Line Treatment for oHCM, Earning Buy Rating from Joseph Pantginis
PremiumRatings
Cytokinetics’ Aficamten Shows Promise as First-Line Treatment for oHCM, Earning Buy Rating from Joseph Pantginis
1d ago
CYTK
Cytokinetics announces results from MAPLE-HCM, met primary endpoint
PremiumThe FlyCytokinetics announces results from MAPLE-HCM, met primary endpoint
2d ago
CYTK
Cytokinetics price target lowered to $53 from $55 at Barclays
Premium
The Fly
Cytokinetics price target lowered to $53 from $55 at Barclays
7d ago
CYTK
Cytokinetics Receives Buy Rating Amid Positive Outlook for Aficamten and Strong Financial Position
Premium
Ratings
Cytokinetics Receives Buy Rating Amid Positive Outlook for Aficamten and Strong Financial Position
7d ago
CYTK
Cytokinetics’ Earnings Call: Balancing Progress and Challenges
PremiumCompany Announcements
Cytokinetics’ Earnings Call: Balancing Progress and Challenges
7d ago
CYTK
Cytokinetics Buy Rating: Strategic Developments and Market Opportunities Drive Optimism Despite FDA Delay
PremiumRatings
Cytokinetics Buy Rating: Strategic Developments and Market Opportunities Drive Optimism Despite FDA Delay
7d ago
CYTK
Cytokinetics: Strong Financials and Promising Pipeline Drive Buy Rating
PremiumRatings
Cytokinetics: Strong Financials and Promising Pipeline Drive Buy Rating
8d ago
CYTK
Cytokinetics price target lowered to $80 from $86 at Citi
PremiumThe Fly
Cytokinetics price target lowered to $80 from $86 at Citi
8d ago
CYTK
Cytokinetics: Hold Rating Amid FDA Delays and Commercial Uncertainties
PremiumRatingsCytokinetics: Hold Rating Amid FDA Delays and Commercial Uncertainties
8d ago
CYTK
Cytokinetics Reports Q1 2025 Financials and Strategic Progress
Premium
Company Announcements
Cytokinetics Reports Q1 2025 Financials and Strategic Progress
8d ago
CYTK
Cytokinetics reports Q1 EPS ($1.36), consensus ($1.36)
Premium
The Fly
Cytokinetics reports Q1 EPS ($1.36), consensus ($1.36)
8d ago
CYTK
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
9d ago
IBO
ADIL
Strategic Opportunity and Management Confidence Underpin Buy Rating for Cytokinetics Despite FDA Delay
PremiumRatings
Strategic Opportunity and Management Confidence Underpin Buy Rating for Cytokinetics Despite FDA Delay
10d ago
CYTK
Cytokinetics (CYTK) Q1 Earnings Cheat Sheet
PremiumPre-Earnings
Cytokinetics (CYTK) Q1 Earnings Cheat Sheet
11d ago
CYTK
Apple reports earnings beat, China weighs trade talks with U.S.: Morning Buzz
PremiumThe Fly
Apple reports earnings beat, China weighs trade talks with U.S.: Morning Buzz
12d ago
BX
DD
Cytokinetics price target lowered to $41 from $47 at UBS
PremiumThe FlyCytokinetics price target lowered to $41 from $47 at UBS
12d ago
CYTK
Cytokinetics Receives Buy Rating from Analyst Joseph Pantginis Due to Promising Developments and Strategic Market Positioning
Premium
Ratings
Cytokinetics Receives Buy Rating from Analyst Joseph Pantginis Due to Promising Developments and Strategic Market Positioning
13d ago
CYTK
Cytokinetics’ Aficamten Faces Market Uncertainty Amid FDA Delays, Prompting Hold Rating
Premium
Ratings
Cytokinetics’ Aficamten Faces Market Uncertainty Amid FDA Delays, Prompting Hold Rating
13d ago
CYTK

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >